Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery

Blood

Volumn 116, Issue 25, 2010, Pages 5734-5737

  Dargaud, Yesim ^a,b   Lienhart, Anne ^a   Negrier, Claude ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ELECTIVE SURGERY; EX VIVO STUDY; FEMALE; HEMOPHILIA; HEMOSTASIS; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBIN TIME;

EID: 78650492660     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-291906     Document Type: Article

References (15)

1. Ingerslev J. Strategies for the treatment of inhibitor patients. Haematologica. 2000;85(suppl. 10):15-20.
2. Astermark J. Treatment of the bleeding in inhibitor patient. Semin Thromb Haemost. 2003;29(suppl 1):77-89.
3. Kraut EH. The use of Feiba for surgery in patients with hemophilia and inhibitors. Hemophilia. 2006;12(suppl 5):20-25. (Pubitemid 44636908)
4. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9(2):119-128. (Pubitemid 28216256)
5. Dargaud Y, Lienhart A, Meunier S, et al. Major surgery in a severe hemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Hemophilia. 2005;11(5):552-558. (Pubitemid 41283127)
6. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(suppl 1):S61-S65. (Pubitemid 28511567)
7. Gabriel DA, Li X, Monroe DM 3rd, Roberts HR. Recombinant human factor VIIa (rFVIIIa) can activate factor FIX on activated platelets. J Thromb Haemost. 2004;2(10):1816-1822. (Pubitemid 40192724)
8. Dargaud Y, Bordet JC, Lienhart A, Negrier C. Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. Semin Hematol. 2008;2(suppl 1):S72-S73. (Pubitemid 351787680)
9. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and hemophilia A plasma. Hemophilia. 2008;14(4):782-786. (Pubitemid 352016035)
10. Hemker HC, Giesen P, Al Dieri R et al. Calibrated automated TG measurement in clotting plasma. Pathophysiol Hemost Thromb. 2003;33(1):4-15.
11. Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with hemophilia A and B. Thromb Haemost. 2005;93(3):475-480. (Pubitemid 40392535)
12. Dargaud Y, Luddington R, Baglin T. Platelet-dependent thrombography: a method for diagnostic laboratories. Br J Haematol. 2006;134(3):323-325. (Pubitemid 43990795)
13. Kasper CK, Aledort LM, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitor. Thromb Diath Haemorrh. 1975;34(2):612.
14. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of NovoSeven® and FEIBA in hemophilia patients with inhibitors. Hemophilia. 2009;15(4):904-910.
15. Nair SC, Dargaud Y, Chitlur M, Srivastava A. Tests of global hemostasis and their applications in bleeding disorders. Hemophilia. 2010;16(suppl 5):85-92.